Immunogenicity and safety among laboratory workers vaccinated with Bexsero® vaccine
Neisseria meningitidis serogroup B is the most prevalent cause of invasive meningococcal disease in Europe and members of laboratories working on meningococci are at risk due to frequent handling. Recommendation for anti-meningococcal vaccination among these workers has been recently updated upon th...
Main Authors: | Eva Hong, Aude Terrade, Muhamed-Kheir Taha |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2017-03-01
|
Series: | Human Vaccines & Immunotherapeutics |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/21645515.2016.1241358 |
Similar Items
-
Product review on the IMD serogroup B vaccine Bexsero®
by: Ala-Eddine Deghmane, et al.
Published: (2022-01-01) -
Systematic literature review on the safety and immunogenicity of rotavirus vaccines when co-administered with meningococcal vaccines
by: Priya Pereira, et al.
Published: (2020-11-01) -
Safety and immunogenicity of a meningococcal B recombinant vaccine when administered with routine vaccines to healthy infants in Taiwan: A phase 3, open-label, randomized study
by: Nan-Chang Chiu, et al.
Published: (2018-05-01) -
The immunogenicity and safety of a Hib-MenAC vaccine: a non-inferiority randomized, observer-blind trial in infants aged 3-5 months
by: Yu-Xiao Wang, et al.
Published: (2017-05-01) -
Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT): A review of the evidence and expert opinion
by: Silvia Ricci, et al.
Published: (2023-12-01)